Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gygax, S. E. Articles by Trama, J. P. Search for Related Content PubMed PubMed Citation Articles by Gygax, S. E. Articles by Trama, J. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3424-3426, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00462-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Antifungal Resistance of Candida glabrata Vaginal Isolates and Development of a Quantitative Reverse Transcription-PCR-Based Azole Susceptibility Assay

Scott E. Gygax,^1,* John-Paul Vermitsky,^1, Sean G. Chadwick,¹ Matthew J. Self,¹ Jessica A. Zimmerman,³ Eli Mordechai,³ Martin E. Adelson,³ and Jason P. Trama²

Antimicrobial Resistance Division,¹ Molecular and Cellular Biology Division,² Medical Diagnostic Laboratories, L.L.C., 2439 Kuser Road, Hamilton, New Jersey 08690³

Received 7 April 2008/ Returned for modification 7 June 2008/ Accepted 24 June 2008

Top ABSTRACT TEXT REFERENCES

 
A multiplex quantitative reverse transcription-PCR assay was developed to detect azole resistance in Candida glabrata, an important opportunistic pathogen that develops resistance rapidly. Resistance was defined as a 3-fold increase in CDR1 expression by this assay, which proved to be 100% sensitive and 95% specific in comparison to the gold standard broth microdilution assay.

Top ABSTRACT TEXT REFERENCES

 
In the United States, Candida fungal infections have increased significantly over the past 3 decades, particularly those due to non-albicans species (2, 3, 6). The emergence of non-albicans species, especially Candida glabrata, is problematic for both immunocompetent and immunocompromised populations. C. glabrata is now recognized as the second most common cause of Candida infections (10 to 30%) and the primary species isolated from diabetic patients (61.3%) and the elderly (51.2%), with mortality rates up to 51% (1, 4, 5, 13, 21). This organism exhibits intrinsically low susceptibility to azole antifungals, as shown in this study and one by Richter et al. (15), in which a majority of isolates are susceptible-dose dependent (S-DD) or resistant (R). Additionally, this organism can rapidly develop resistance in both the clinical setting and within the laboratory (14, 19).

Identifying the species and susceptibility of an isolate involved in infection is imperative for determining the proper course of treatment. Surveillance programs performed over the past few decades have demonstrated that although azole resistance is rare in Candida albicans isolates (<1%), it is becoming very common among isolates of C. glabrata (up to 15%) and other non-albicans species (10, 15, 16). Current practices for determining the susceptibility of a particular isolate involve the microbroth dilution assay (MBD) outlined in the M27-2A document of the Clinical Laboratory Standards Institute (CLSI) (9). Although this assay is quite effective, results can take upwards of a week to obtain and the need to develop a more rapid, yet still reliable, method for determining the susceptibility of yeast isolates is warranted.

The purpose of this study was to examine the susceptibility of and establish azole resistance markers for C. glabrata. The predominant mechanism of azole resistance in C. glabrata is the increased expression of multidrug transporter genes CDR1 and PDH1 under the transcriptional regulation of PDR1 (8, 14, 17, 18, 19, 20). In this study, all three genes were examined for upregulated expression by a quantitative reverse transcription (qRT)-PCR assay. Recent publications have established similar assays for C. albicans (7, 11) but not for C. glabrata, for which resistance is far more prevalent.

C. glabrata isolates were retrieved from cervicovaginal swabs that were tested using species-specific in-house real-time PCR assays and confirmed on BBL CHROMagar Candida plates. Azole susceptibility testing was performed on 175 clinical isolates by MBD for fluconazole, voriconazole, and miconazole according to the CLSI guidelines outlined in document M27-A2 (9). Our C. glabrata isolates demonstrated R and S-DD profiles (26.9% and 42.2%, respectively) (Table 1) similar to those of previously reported vulvovaginal candidiasis isolates (15.2% and 51.8%) (15).

View this table: [in this window] [in a new window]

TABLE 1. Susceptibility of 175 C. glabrata isolates

A qRT-PCR assay was developed to detect C. glabrata azole resistance. RNA from cells grown in culture to mid-log phase was isolated using the Qiagen RNeasy kit and treated with RQ1 DNase (Promega). A total of 50 ng of RNA was used in the qRT-PCRs. The primers and probes used are listed in Table 2. The levels of mRNA of the multidrug resistance (MDR) genes (CDR1, PDH1, and PDR1) and the actin housekeeping gene (ACT1) were measured using a One-Step qRT-PCR on the Stratagene Mx3000P QPCR system (Stratagene). The expression levels of the ACT1 gene were found to be consistent among the susceptible (S), S-DD, and R isolates. The qRT-PCR assay was performed in triplicate, with independent amplifications using the same RNA for the gene of interest (CDR1, PDH1, or PDR1) and the ACT1 control in a duplex reaction. The expression levels of the MDR genes were found to be consistent among the S isolates (Fig. 1). Five S clinical isolates (MICs of 8, 8, 4, 4, and 2 µg/ml) were chosen to determine a consistent baseline expression profile for each assay. The gene expression level relative to this panel of S isolates was expressed as 2^–CT. Furthermore, the qRT-PCR assay was specific for C. glabrata as it did not cross-react with a panel of 88 different fungal, bacterial, and viral pathogens, including other Candida species (data not shown).

View this table: [in this window] [in a new window]

TABLE 2. Primers and dually labeled probes developed in this study

View larger version (15K): [in this window] [in a new window]

FIG. 1. Gene expression profiles within the susceptibility groups. Clinical isolates were tested for fluconazole susceptibility by MBD (9), and the results were compared to qRT-PCR expression levels of CDR1 (A), PDH1 (B), and PDR1 (C). The heavy solid horizontal bars represent the median values. The horizontal dotted line represents a twofold increase in expression level above that for the susceptible panel. The vertical dotted lines distinguish the three susceptibility groups as determined by CLSI breakpoints for Candida species.

Ten swabs from each of the three susceptibility groups (S, S-DD, and R) previously tested by MBD (Table 1) were randomly chosen. Three isolates from each swab were used in the qRT-PCR azole susceptibility assay. Nonsusceptible isolates (S-DD and R) were defined by a 2-fold increase in any of the three MDR genes. Compared to MBD, the qRT-PCR assay detected nonsusceptible isolates with 80% sensitivity, 100% specificity, 100% positive predictive value, and 71% negative predictive value. For determining resistance, a more stringent cutoff of a 3-fold increase in expression of CDR1 alone could be used as the predominant molecular marker with 100% sensitivity, 95% specificity, 91% positive predictive value, and 100% negative predictive value. All of the isolates tested from the 10 resistant swabs showed 3-fold-increased expression levels of CDR1. The single false positive was an S-DD swab with a MIC of 32 µg/ml. All 10 of the susceptible swabs tested had increases of less than twofold for all three molecular markers. The three isolates tested from each of 29 swabs demonstrated a consistent susceptibility phenotype, as characterized by both MBD and qRT-PCR assays. Interestingly, one swab sample contained two isolates that tested susceptible and one isolate that was highly resistant. Although a rare occurrence, this result supports the need for selecting multiple colonies per swab when the qRT-PCR assay is performed.

Apart from providing the susceptibility profile of C. glabrata cervicovaginal isolates, our study proposes the use of molecular markers to determine the susceptibility of a particular isolate to azole antifungals. qRT-PCR is now recognized as a reliable method for evaluating gene expression. In this study, we found that a 3-fold change in the expression of the C. glabrata CDR1 gene based on a qRT-PCR assay determined azole resistance with 100% sensitivity and 95% specificity. Moreover, the qRT-PCR assay provides a simple, efficient, and cost-effective method for early detection, identification, and azole susceptibility testing in as little as 30 h for a particular C. glabrata isolate. Conversely, the conventional MBD (9) is labor-intensive, requiring colony isolation, identification to the species level, and culturing that can take upwards of 72 h in addition to the time of the assay itself. Therefore, the qRT-PCR assay would assist in expediting a proper course of treatment and would minimize the likelihood of selecting for resistant isolates through treatment with ineffective levels of azole antifungals.

 
We thank Pfizer for their generous gift in providing voriconazole for this study.

 
* Corresponding author. Mailing address: Antimicrobial Resistance Division, Department of Research and Development, Medical Diagnostic Laboratories, L.L.C., 2439 Kuser Road, Hamilton, NJ 08690. Phone: (609) 570-1015. Fax: (609) 570-1030. E-mail: sgygax{at}mdlab.com

Published ahead of print on 30 June 2008.

These authors have contributed equally to this work.

Top ABSTRACT TEXT REFERENCES

 

1
1. Bader, M. S., S. M. Lai, V. Kumar, and D. Hinthorn. 2004. Candidemia in patients with diabetes mellitus: epidemiology and predictors of mortality. Scand. J. Infect. Dis. 36:860-864.[Medline]
2
2. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 16:86S-89S.
3
3. Berrouane, Y. F., L. A. Herwaldt, and M. A. Pfaller. 1999. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J. Clin. Microbiol. 37:531-537.[Abstract/Free Full Text]
4
4. Dan, M., R. Segal, V. Marder, and A. Leibovitz. 2006. Candida colonization of the vagina in elderly residents of a long-term-care hospital. Eur. J. Clin. Microbiol. Infect. Dis. 25:394-396.[CrossRef][Medline]
5
5. Goswami, D., R. Goswami, U. Banerjee, V. Dadhwal, S. Miglani, A. A. Lattif, and N. Kochupillai. 2006. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole. J. Infect. 52:111-117.[CrossRef][Medline]
6
6. Kao, A. S., M. E. Brandt, W. R. Prutti, L. A. Conn, B. A. Perkins, D. S. Stephens, W. S. Baughman, A. L. Reingold, G. A. Rothrock, M. A. Pfaller, R. W. Pinner, and R. A. Hajjeh. 1999. The epidemiology of candidemia in two U.S. cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170.[CrossRef][Medline]
7
7. Kofla, G., and M. Ruhnke. 2007. Development of a new real-time TaqMan PCR assay for quantitative analyses of Candida albicans resistance genes expression. J. Microbiol. Methods 68:178-183.[CrossRef][Medline]
8
8. Miyazaki, H., Y. Miyazaki, A. Gerber, T. Parkinson, C. Hitchcock, D. J. Falconer, D. J. Ward, K. Marsden, and J. E. Bennet. 1998. Fluconazole resistance associated with drug efflux and increased transcription of a drug transporter gene, PDH1, in Candida glabrata. Antimicrob. Agents Chemother. 42:1695-1701.[Abstract/Free Full Text]
9
9. NCCLS/CLSI. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed., M27-A2. NCCLS/CLSI, Wayne, Pa.
10
10. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Harold, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.[Abstract/Free Full Text]
11
11. Park, S., and D. S. Perlin. 2005. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb. Drug Resist. 11:232-238.[CrossRef][Medline]
12
12. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.[Abstract/Free Full Text]
13
13. Ray, D., R. Goswami, U. Banerjee, V. Dadhwal, D. Goswami, P. Mandal, V. Sreenivas, and N. Kochupillai. 2007. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 30:312-317.[Abstract/Free Full Text]
14
14. Redding, S. W., W. R. Kirkpatrick, S. Saville, B. J. Coco, W. White, A. Fothergill, M. Rinaldi, T. Eng, T. F. Patterson, and J. Lopez-Ribot. 2003. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 41:619-622.[Abstract/Free Full Text]
15
15. Richter, S. S., R. P. Galask, S. A. Messer, R. J. Hollis, D. J. Diekema, and M. A. Pfaller. 2005. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Micobiol. 45(5):2155-2162.
16
16. Safdar, A., D. Armstrong, E. W. Cross, and D. S. Perlin. 2002. Prospective epidemiologic analysis of triazole-resistant nosocomial Candida glabrata isolated from patients at a comprehensive cancer center. Int. J. Infect. Dis. 6:198-201.[CrossRef][Medline]
17
17. Sanglard, D., F. Ischer, D. Calabrese, P. A. Majcherczyk, and J. Bille. 1999. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43:2753-2765.[Abstract/Free Full Text]
18
18. Sanguinetti, M., B. Posteraro, B. Fiori, S. Ranno, R. Torelli, and G. Fadda. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679.[Abstract/Free Full Text]
19
19. Vermitsky, J.-P., and T. D. Edlind. 2004. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob. Agents Chemother. 48(10):3773-3781.[Abstract/Free Full Text]
20
20. Vermitsky, J.-P., T. Liu, T. D. Edlind, and P. D. Rogers. 2006. PDR1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol. Microbiol. 61:704-722.[CrossRef][Medline]
21
21. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.[CrossRef][Medline]

---

Antimicrobial Agents and Chemotherapy, September 2008, p. 3424-3426, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00462-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gygax, S. E. Articles by Trama, J. P. Search for Related Content PubMed PubMed Citation Articles by Gygax, S. E. Articles by Trama, J. P.